Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

September 10, 2025

Findings reveal that cancer genomics similar to other populations, but with some distinctive features.

September 04, 2025

Findings suggest that treatment with an FGFR4 inhibitor can disrupt tumor spread in pancreatic cancer.

September 02, 2025

Health services company recognizes joint care offered through collaboration with Roswell Park Oishei Children’s Hospital.

August 18, 2025

Research shows that blocking CXCR2 receptor reduced tumor growth and improved survival; clinical trial underway.

August 12, 2025

Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies.

July 31, 2025

A New York cancer center appears on list for second consecutive year, based on anonymous employee surveys

July 22, 2025

Doctors join cancer center with expertise in surgical and medical oncology, pathology, dermatology, anesthesia.

July 17, 2025

Research centers across New York State are collaborating to develop cell therapies for cancer to expand progress in the emerging field of cell therapy.

June 30, 2025

Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences

June 23, 2025

Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.

June 19, 2025

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

June 16, 2025

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

May 31, 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses the design of an observational study investigating immunologic changes with venetoclax in CLL.

May 30, 2025

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

May 30, 2025

Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.

May 19, 2025

Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.

May 12, 2025

The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.

May 12, 2025

Renier Brentjens, MD, PhD, discusses the current landscape of CAR T-cell agents in patients with solid tumors.

April 25, 2025

Matthew Cortese, MD, MPH, discusses the rationale for an analysis of the immunologic activity of venetoclax in patients with chronic lymphocytic leukemia.

April 24, 2025

Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.